20% of masses resolve spontaneously within 2 years.
ONCOLOGY
Fully funded by 
Content independently selected
-
Ovarian cysts: observation a safe alternative to surgery in IOTA5 -
Results from the International Ovarian Tumor Analysis Phase 5 (IOTA5) study, the largest of its kind to date.
-
Breastfeeding may protect against ovarian cancer for 30+ years Breastfeeding for as little as 3 months shows protective effect.
-
Ovarian cancer: niraparib similarly effective in elderly patients Post hoc analysis showed similar PFS benefit regardless of age, BRCA mutation.
-
Randomised study of olaratumab plus liposomal doxorubicin in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.
-
Recurrent ovarian cancer: cabozantinib fails phase 2 trial OS and toxicities were worse vs weekly paclitaxel.
-
Expert Commentary – Ovarian cancer: main improvements in 2018 PARP inhibitors in recurrent ovarian cancer increase PFS. But if used more and more as first-line therapy, what will we do with PARP inhibitors in later lines?
-
BRCA+ ovarian cancer: heavily treated patients retain chemosensitivity in Spanish study Primary PFI, platinum-based CT, and PARP-inhibitors strongly predict outcomes.
-
KEYNOTE-028: pembrolizumab shows efficacy in ovarian cancer Active in advanced recurrent disease, with safety profile consistent vs other studies.
-
EOC: 1 in 7 women develop VTE within 6 months of debulking surgery Guidelines do not recommend VTE prophylaxis for outpatients.
-
Advanced EOC: timely ACT completion yields optimal outcomes Shorter regimens and delays of >4 weeks attenuate survival benefit.
-
Ovarian cancer: add-on BVZ boosts PFS regardless of residual disease Post hoc analysis of ICON7 shows OS improvement in high-risk group.
-
Simple ovarian cysts not tied to cancer Can be considered normal findings, no surveillance needed.
-
Tubo-ovarian cancer: NACT, primary debulking offer similar OS NACT superior for stage IV disease in pooled analysis of EORTC 55971, CHORUS.